Bayer Got Private EPA Access, Then Got Government Protection

Analysis of: EPA chief met with Bayer CEO over supreme court fight, agency records show
The Guardian | March 12, 2026

TL;DR

Bayer's CEO met privately with EPA officials to discuss killing cancer lawsuits—then the Trump administration delivered exactly what the corporation wanted. This is regulatory capture in real time: corporate profits trump public health when capital has direct access to state power.

Analytical Focus:Class Analysis Historical Context Contradictions

This Guardian investigation provides a textbook case of what Marxists call the capitalist state functioning as an executive committee for managing the affairs of the bourgeoisie. Bayer's CEO secured a private meeting with the EPA's top officials to discuss the corporation's legal strategy for escaping liability for cancer claims. Within months, the Trump administration delivered a comprehensive package of support: urging the Supreme Court to hear Bayer's case, invoking the Defense Production Act to protect glyphosate production, and filing an amicus brief fully backing the corporation's position. The class dynamics here are starkly visible. On one side: a multinational corporation with direct access to regulatory decision-makers, capable of arranging meetings with agency administrators to discuss how to avoid compensating workers and consumers harmed by its products. On the other: tens of thousands of cancer victims whose access to justice depends on a legal system now being actively undermined by the state apparatus ostensibly designed to protect public health. The revolving door between industry and regulation—exemplified by Nancy Beck's journey from the American Chemistry Council to EPA leadership—demonstrates how capital reproduces its influence within state institutions. What makes this case particularly illustrative is how it exposes the contradiction between the state's legitimating function (protecting public welfare) and its structural role serving capital accumulation. The EPA exists nominally to protect environmental and human health, yet here it operates as a facilitator for corporate legal strategy. The Defense Production Act, designed for national emergencies, becomes a tool for shielding a German corporation from accountability to American workers. This isn't corruption as individual moral failing—it's the normal functioning of a state embedded in capitalist social relations.

Class Dynamics

Actors: Transnational corporate capital (Bayer), State regulatory apparatus (EPA officials), Political appointees with industry backgrounds, Cancer victims and their families, Agricultural workers exposed to glyphosate, Consumer advocacy organizations, Environmental NGOs

Beneficiaries: Bayer shareholders and executives, Chemical industry broadly, Corporate legal strategies seeking preemption precedents, Trump administration allies in agribusiness

Harmed Parties: Tens of thousands of cancer victims seeking compensation, Agricultural workers with ongoing glyphosate exposure, Future potential victims denied warning labels, Public health infrastructure, Regulatory legitimacy

The power asymmetry is extreme: Bayer's CEO secures private meetings with top regulators to strategize about litigation, while cancer victims are represented only through consumer advocacy groups who, as one attorney noted, were never given equivalent access. The revolving door between industry (American Chemistry Council) and regulatory positions (Nancy Beck at EPA) institutionalizes corporate influence. State power is deployed not neutrally but in service of capital—the Defense Production Act and solicitor general's office both mobilized to protect corporate profits from accountability to harmed workers and consumers.

Material Conditions

Economic Factors: Billions in existing settlements and jury verdicts threatening Bayer's bottom line, Glyphosate as cornerstone of industrial agricultural production, Legal preemption doctrine as mechanism to socialize corporate risk, Regulatory capture reducing compliance costs for chemical industry

Bayer occupies a monopolistic position in herbicide production following its Monsanto acquisition, making glyphosate central to capitalist agricultural relations globally. The contradiction emerges between the social character of agricultural production (feeding populations) and the private appropriation of both profits and decisions about acceptable harm. Workers and consumers bear the health costs externalized by production for profit, while corporations seek legal mechanisms to avoid internalizing these costs.

Resources at Stake: Billions in potential legal liabilities, Regulatory precedent affecting all chemical manufacturers, Supreme Court preemption doctrine with broad implications, Glyphosate market dominance, EPA's legitimacy as public health regulator

Historical Context

Precedents: Tobacco industry's decades-long campaign to avoid cancer liability, Chemical industry's successful preemption arguments in pesticide regulation, Reagan-era regulatory capture establishing industry-friendly EPA patterns, Citizens United expanding corporate political influence, Revolving door between chemical lobby and EPA dating to agency's founding

This episode represents the mature neoliberal pattern of regulatory capture, where the state's ostensible public health function is subordinated to facilitating capital accumulation. The strategy of seeking federal preemption to override state consumer protection follows a well-established corporate playbook: when jury verdicts threaten profits, seek legal doctrines that eliminate accountability entirely. This reflects what scholars call 'accumulation by dispossession'—using state power to protect corporate wealth extraction from democratic accountability. The involvement of a German multinational also demonstrates how transnational capital operates across borders while using national state apparatuses as instruments.

Contradictions

Primary: The fundamental contradiction between the EPA's legitimating function (protecting public health) and its structural role serving capital accumulation is exposed when the agency actively assists a corporation in avoiding accountability for mass harm to public health.

Secondary: Contradiction between 'rule of law' ideology and differential access to legal/political system based on class position, Contradiction between national sovereignty rhetoric and serving transnational corporate interests, Contradiction between MAHA movement's anti-chemical rhetoric and administration's pro-Bayer actions, Contradiction between democratic accountability and regulatory capture

The immediate trajectory favors capital: the Supreme Court case may establish preemption doctrine that shields all chemical manufacturers from failure-to-warn claims. However, this resolution intensifies the underlying contradiction by further delegitimizing regulatory institutions. The MAHA movement's presence in the article hints at potential fractures—when administration allies also demand pesticide restrictions, the coalition serving chemical capital becomes unstable. The long-term trajectory depends on whether working-class movements can challenge both corporate power and the state structures that serve it.

Global Interconnections

This case connects to global patterns of transnational corporate power operating through national state apparatuses. Bayer, a German corporation, deploys American regulatory and legal systems to protect profits extracted globally. This reflects imperialism's contemporary form: less direct territorial control, more the subordination of state functions to transnational capital accumulation. The glyphosate question itself is global—the herbicide's dominance in industrial agriculture worldwide means this legal precedent affects agricultural workers and consumers across borders. The case also illuminates how capitalist crisis management operates. Facing billions in liabilities that threaten accumulation, capital doesn't simply accept market outcomes but mobilizes state power to restructure the rules. The Defense Production Act's invocation—designed for wartime emergencies—to protect a corporation from lawsuits demonstrates the plasticity of state power when capital's interests are at stake. This 'socialism for corporations' coexists with market discipline for workers, revealing the class character of state intervention.

Conclusion

This case demonstrates why regulatory reform within capitalism faces structural limits—the state's embeddedness in capitalist social relations means 'capture' isn't an aberration but a tendency built into the system. For working-class movements, the implications are clear: relying on regulatory agencies to protect public health means relying on institutions structurally oriented toward capital. The path forward requires building independent power capable of challenging both corporate prerogatives and the state structures that serve them. The cancer victims in this case had their best success through jury trials—direct confrontation with corporate harm before ordinary people—before capital mobilized state power to foreclose that avenue. This suggests the terrain of struggle: building collective power that doesn't depend on regulatory goodwill, while exposing the class character of 'neutral' state institutions.

Suggested Reading

• The State and Revolution by V.I. Lenin (1917) Lenin's analysis of the state as an instrument of class rule directly illuminates how regulatory agencies ostensibly serving public interest actually function to protect capital accumulation.
• The Shock Doctrine by Naomi Klein (2007) Klein's documentation of how crises and emergency powers are deployed to advance corporate interests parallels the Defense Production Act's use here to shield Bayer from accountability.
• Prison Notebooks (Selections) by Antonio Gramsci (1935) Gramsci's concept of hegemony helps explain how regulatory capture operates through both coercion and consent—the 'normal regulatory process' framing naturalizes corporate access to state power.